Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company advancing cancer therapies. Company updates center on Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 receptor.
Recurring news includes quarterly financial results, product revenue for Revuforj and Niktimvo, collaboration revenue from Niktimvo commercialization with Incyte, clinical data presentations in acute leukemia, chronic graft-versus-host disease and related indications, FDA-related product updates, investor conference activity and inducement equity grants under Nasdaq listing rules.
Syndax Pharmaceuticals (Nasdaq: SNDX) is hosting an R&D Event on July 14, 2026, to showcase its late-stage programs and unveil new pipeline assets, including SNDX-4321 and SNDX-62122.
SNDX-4321 is a novel, mutant-selective, allosteric EGFR inhibitor licensed worldwide for development and commercialization in EGFR-mutated NSCLC, with an IND submission targeted by year-end 2026 and a Phase 1 trial planned for 2027. SNDX-62122, the first candidate from the company’s internally developed, wholly owned next-generation menin inhibitor library, is being advanced for myelofibrosis, with an IND and Phase 1 trial expected in 2027, informed by a revumenib MF proof-of-principle study starting in 4Q26. The event will also review ongoing late-stage programs for Revuforj (revumenib) and Niktimvo (axatilimab-csfr), including a Phase 2 axatilimab trial in IPF expected to deliver topline data in 4Q26.
Syndax Pharmaceuticals (Nasdaq:SNDX) granted inducement stock options to eight new employees on July 1, 2026 under its 2023 Inducement Plan. The awards cover up to 250,700 shares of common stock and vest over four years, subject to continued employment-based service conditions.
Syndax (Nasdaq:SNDX) reported new Revuforj® (revumenib) data at EHA 2026 across multiple acute leukemia subtypes and settings.
Highlights include 82% ORR in the ROAR real-world study, 97% CRc in a frontline Phase 1 AML trial, 95% estimated 1‑year OS post-transplant in AUGMENT‑101, 28% ORR in NUP98r disease, and 88% ORR in the Phase 2 SAVE combination trial.
Syndax (Nasdaq:SNDX) reported Phase 1/2 SAVE trial data for all-oral Revuforj (revumenib) + decitabine/cedazuridine + venetoclax in relapsed/refractory NPM1m, KMT2Ar, and NUP98r AML.
Among 42 heavily pretreated patients, ORR was 88%, CRc 71%, CR/CRh 60%, MRD negativity in CRc 80%, 45% proceeded to transplant, and safety was described as generally manageable.
Syndax Pharmaceuticals (Nasdaq:SNDX) granted stock option inducement awards under Nasdaq Listing Rule 5635(c)(4) to four new employees on June 1, 2026. The options cover up to 66,700 shares of common stock under the 2023 Inducement Plan and vest over four years.
Syndax (NASDAQ:SNDX) entered into privately negotiated subscription agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031. Closing is expected on June 10, 2026. Net proceeds of about $243 million are earmarked for general corporate purposes, including R&D and commercialization.
The Notes are senior unsecured, bear 2.25% semiannual interest, and are initially convertible at 40.3894 shares per $1,000 principal (conversion price about $24.76, a 35% premium to the June 3, 2026 share price). Syndax can redeem from June 20, 2029, subject to a stock price condition.
Syndax (Nasdaq:SNDX) reported new Revuforj® (revumenib) data from ASCO 2026, including post-transplant and pharmacokinetic results.
In 24 adults and children with high-risk acute leukemia resuming revumenib after HSCT, the 2-year overall survival rate was 90% vs a historical 51%, with low relapse rates and manageable thrombocytopenia. PK data from 335 patients showed flexible dosing with gastric acid reducers, CYP3A4 inhibitors, and varying food conditions.
Syndax Pharmaceuticals (Nasdaq:SNDX) will host an R&D Day on July 14, 2026, at 8:30 AM ET in New York City. Management and key opinion leaders will present updates on late-stage revumenib and axatilimab programs and discuss ongoing trials.
The event will also cover new early-stage assets and plans to leverage company capabilities to bring additional cancer treatment options to patients. A live webcast and limited-time replay will be available in the Investor section of www.syndax.com.
Syndax (Nasdaq:SNDX) announced that four Revuforj (revumenib) abstracts were accepted for presentation at ASCO 2026, including an oral post-transplant maintenance study in 21 adults and children with acute leukemia.
Additional posters cover revumenib pharmacokinetics and designs of two phase 3 trials in newly diagnosed NPM1m or KMT2Ar AML.
Syndax Pharmaceuticals (Nasdaq:SNDX) announced participation in several upcoming investor conferences featuring fireside chats with CEO Michael A. Metzger and the management team.
Events include TD Cowen’s Oncology Innovation Summit, the Jefferies Global Healthcare Conference, and the Goldman Sachs Global Healthcare Conference, with live and replay webcasts via Syndax’s investor website.